News
Janssen claims FDA okay for would-be Tagrisso rival Rybrevan...
Johnson & Johnson's Janssen division has claimed a first approval in the US for its bispecific antibody Rybrevant as a treatment for EGFR-mutated non-small cell lung cancer (NSCLC).
